文献速递淋巴瘤

伊布替尼联合帕博西尼治疗经治套细胞淋巴瘤的1期试验

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
PubMed 文献 · Blood · 2019-01-28

这项1期试验评估伊布替尼联合帕博西尼在经治套细胞淋巴瘤患者中的剂量、安全性和初步活性,2014年8月至2016年6月共入组27例患者,最大耐受剂量为伊布替尼560 mg每日联合帕博西尼100 mg每28天周期第1至21天,总缓解率67%、完全缓解率37%,2年无进展生存率59.4%。

要点

  • 最大耐受剂量为伊布替尼560 mg每日联合帕博西尼100 mg每28天周期第1至21天。
  • 剂量限制性毒性为3级皮疹,最常见3至4级毒性为中性粒细胞减少(41%)。
  • 总缓解率67%、完全缓解率37%,中位随访25.6个月时2年无进展生存率59.4%。

核心结论

  • 伊布替尼联合帕博西尼在经治套细胞淋巴瘤患者中确定了最大耐受剂量,并显示出初步活性,一项进一步评估疗效的2期多中心临床试验正在进行中。

研究设计与样本

  • 1期试验,评估帕博西尼联合伊布替尼在经治套细胞淋巴瘤患者中的剂量、安全性和初步活性。
  • 2014年8月至2016年6月共入组27例患者(21例男性,6例女性)。
  • 试验注册号为NCT02159755。

主要发现

  • 最大耐受剂量为伊布替尼560 mg每日联合帕博西尼100 mg每28天周期第1至21天。
  • 剂量限制性毒性为3级皮疹。
  • 最常见3至4级毒性包括中性粒细胞减少(41%)、血小板减少(30%)、高血压(15%)、发热性中性粒细胞减少(15%)和肺部感染(11%)。
  • 总缓解率为67%,完全缓解率为37%。
  • 中位随访25.6个月时,2年无进展生存率为59.4%,2年缓解持续时间为69.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary human MCL cells and MCL cell lines expressing wild-type Bruton's tyrosine kinase (BTK). Therefore, we conducted a phase 1 trial to evaluate the dosing, safety, and preliminary activity of palbociclib plus ibrutinib in patients with previously treated mantle cell lymphoma. From August 2014 to June 2016, a total of 27 patients (21 men, 6 women) were enrolled. The maximum tolerated doses were ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle. The dose-limiting toxicity was grade 3 rash. The most common grade 3 to 4 toxicities included neutropenia (41%), thrombocytopenia (30%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%). The overall and complete response rates were 67% and 37%, and with a median follow-up of 25.6 months, the 2-year progression-free survival was 59.4% and the 2-year response duration was 69.8%. A phase 2 multicenter clinical trial to further characterize efficacy is now ongoing. The current trial was registered at www.clinicaltrials.gov as #NCT02159755.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019. PMID: 30692121. doi:10.1182/blood-2018-11-886457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。